2 hours ago
1
- Rapport Therapeutics (NASDAQ:RAPP) surged 23% in after-hours trading Friday after announcing that it would release top-line phase 2a data on RAP-219, its candidate drug-resistant focal onset seizures.
- The company is also expected to release a primary endpoint analysis of the
English (US) ·